ABOUT ETON PHARMACEUTICALS
Eton Pharmaceuticals, Inc. is a Deer Park, Illinois-based biopharmaceutical company focused on developing and commercializing innovative products utilizing the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway. Our mission is to advance healthcare through the introduction of innovative medicines that are affordable and available to all patients.
Leadership
Sean Brynjelsen is CEO of Eton Pharma and a member of the board of directors. He brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.
Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.
Sean Brynjelsen is CEO of Eton Pharma and a member of the board of directors. He brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.
Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.
Wilson Troutman is CFO of Eton Pharma. Mr. Troutman has more than 30 years of financial and accounting experience. Throughout his career, Wilson has led financial departments for both private start-ups and large public companies. Mr. Troutman was previously the CFO of Omeda Communications, a private data-analytics and data storage company, and from 2004 to 2012 he was the Corporate Controller and Treasurer at Akorn Inc, with responsibilities including Sarbanes-Oxley implementation, SEC reporting, and cash management.
Wilson has an M.B.A. from the University of Chicago, an undergraduate degree in Accounting from the University of Illinois-Urbana, and is a Certified Public Accountant(CPA).
Wilson Troutman is CFO of Eton Pharma. Mr. Troutman has more than 30 years of financial and accounting experience. Throughout his career, Wilson has led financial departments for both private start-ups and large public companies. Mr. Troutman was previously the CFO of Omeda Communications, a private data-analytics and data storage company, and from 2004 to 2012 he was the Corporate Controller and Treasurer at Akorn Inc, with responsibilities including Sarbanes-Oxley implementation, SEC reporting, and cash management.
Wilson has an M.B.A. from the University of Chicago, an undergraduate degree in Accounting from the University of Illinois-Urbana, and is a Certified Public Accountant(CPA).
Bharathi Devarakonda is Senior Vice President of Regulatory Affairs and Product Development. She is responsible for overseeing development and regulatory activities for all of Eton’s pipelines products.
Dr. Devarakonda has significant experience in the pharmaceutical product development and regulatory submission activities of both NDA and ANDA filings. She has worked in product development and regulatory affairs for a number of premier pharmaceutical companies, including Morton Grove Pharmaceuticals (acquired by Wockhardt), Akorn Inc, Hospira(acquired by Pfizer), Rockwell Medical,Inc., and Medefil, Inc. During her career, she has filed more than 80 original NDA, ANDA, and ANADA applications with the FDA. Dr. Devarakonda has a Ph.D and M.S. in Pharmaceutics, a B.S. in Pharmacy, and has significant academic research experience in formulation development and drug delivery.
Bharathi Devarakonda is Senior Vice President of Regulatory Affairs and Product Development. She is responsible for overseeing development and regulatory activities for all of Eton’s pipelines products.
Dr. Devarakonda has significant experience in the pharmaceutical product development and regulatory submission activities of both NDA and ANDA filings. She has worked in product development and regulatory affairs for a number of premier pharmaceutical companies, including Morton Grove Pharmaceuticals (acquired by Wockhardt), Akorn Inc, Hospira(acquired by Pfizer), Rockwell Medical,Inc., and Medefil, Inc. During her career, she has filed more than 80 original NDA, ANDA, and ANADA applications with the FDA. Dr. Devarakonda has a Ph.D and M.S. in Pharmaceutics, a B.S. in Pharmacy, and has significant academic research experience in formulation development and drug delivery.
Board Members
Sean Brynjelsen
Sean Brynjelsen is CEO of Eton Pharma and a member of the board of directors. He brings to the company more than 20 years of pharmaceutical industry experience, with particular expertise in business development and product development. Prior to joining Eton, Mr. Brynjelsen was Executive Vice President of Business Development at Sagent Pharmaceuticals, a generic injectable company that was acquired by Nichi-Iko Pharmaceuticals. Prior to Sagent, he was Senior Vice President of Global Business Development at Akorn Inc, a pharmaceutical company specializing in ophthalmic and injectable products.
Early in his career, Mr. Brynjelsen spent more than 10 years in product development focused on injectable pharmaceuticals at Baxter, Abbott, and Hospira. He has an MBA from the University of Notre Dame, and a Masters of Science in Chemistry and a Bachelor of Science in Chemistry from the University of Illinois.
Mark Baum
Mark L. Baum is the founder and CEO of Imprimis Pharmaceuticals whose mission is to provide patients and physicians with innovative and affordable ophthalmic drugs in the ocular surgery, glaucoma, and dry eye disease markets. Mr. Baum is also a founder and board member of Eton Pharmaceuticals and Surface Pharmaceuticals, as well as a board member and chairman of the audit committee of Ideal Power. Mr. Baum was named by Ernst & Young LLP as the 2017 Entrepreneur of the Year™ in the life sciences category for the San Diego region. Prior to Imprimis, as the founder of TBLF, LLC, a private investment fund, Mr. Baum made more than 200 investments into more than 40 private and public companies. In 1999, Mr. Baum founded YesRx, an HIV-focused pharmacy business. Mr. Baum’s advocacy for drug pricing and accessibility issues has been reflected as an Op-Ed contributor for the Wall Street Journal and through appearances on CBS, CNN, MSNBC, Fox Business, Bloomberg and Al Jazeera. Mr. Baum is a 1995 cum laude graduate of The University of Texas at Arlington and a 1997 graduate of California Western School of Law.
Dr. Norbert Riedel
Dr. Norbert Riedel is the CEO of Aptinyx. Prior to joining Aptinyx, Dr. Riedel was president and CEO of Naurex, the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, Dr. Riedel served various roles at Baxter International including corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst Marion Roussel (now Sanofi). Dr. Riedel serves on the boards of Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization.
Charles Casamento
Charles Casamento was formerly the CEO of Questcor, where he acquired H.P Acthar Gel®. He is currently an Executive Director and Principal of The Sage Group, a healthcare advisory group. He has led five start up companies which were successfully taken public during his tenure, and has served on the board of twelve public companies.
Paul V. Maier
Paul V. Maier currently serves as a financial advisor to the life science industry. Mr. Maier is the former CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc. and has over 25 years experience as a senior executive in biotechnology and specialty pharmaceutical companies. Mr. Maier has served on the boards of eight companies and currently serves as Audit Committee Chair on four public life science companies. Mr. Maier received an M.B.A from Harvard Business School and a B.S. from Pennsylvania State University. Mr. Maier is also an Executive Partner at the College of William & Mary Mason School of Business.
©2017 by Eton Pharmaceuticals
21925 W. Field Pkwy, Suite 235
Deer Park, IL 60010